{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:23:34Z","timestamp":1774520614555,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Stichting BeterKeten"},{"name":"Dutch National MS Foundation","award":["OZ2021-019"],"award-info":[{"award-number":["OZ2021-019"]}]},{"name":"Dutch National MS Foundation","award":["2019-019"],"award-info":[{"award-number":["2019-019"]}]},{"DOI":"10.13039\/100031624","name":"Albert Schweitzer Hospital","doi-asserted-by":"crossref","award":["Stipendium 2021-012"],"award-info":[{"award-number":["Stipendium 2021-012"]}],"id":[{"id":"10.13039\/100031624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100031624","name":"Albert Schweitzer Hospital","doi-asserted-by":"crossref","award":["GoedIdee Subsidie"],"award-info":[{"award-number":["GoedIdee Subsidie"]}],"id":[{"id":"10.13039\/100031624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","award":["23-490g"],"award-info":[{"award-number":["23-490g"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00415-026-13701-8","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:23:00Z","timestamp":1772695380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3460-9948","authenticated-orcid":false,"given":"Romy A. M.","family":"Klein Kranenbarg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelijn M.","family":"Blok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Melisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Asahaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiaan","family":"de Brabander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franka","family":"Claes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Hoppenbrouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naghmeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luuk","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny","family":"Samijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrijs","family":"Wokke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"de Beukelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"13701_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1120541","author":"XY Zhang","year":"2023","unstructured":"Zhang XY, Song Y, Wei ZQ, Chen X, Zhuang XJ, Yi L (2023) The prevalence and risk factors of anxiety in multiple sclerosis: a systematic review and meta-analysis. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2023.1120541","journal-title":"Front Neurosci"},{"key":"13701_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100484","author":"DS Peres","year":"2022","unstructured":"Peres DS, Rodrigues P, Viero FT, Frare JM, Kudsi SQ, Meira GM, Trevisan G (2022) Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis. Brain Behav Immun Health. https:\/\/doi.org\/10.1016\/j.bbih.2022.100484","journal-title":"Brain Behav Immun Health"},{"key":"13701_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","volume":"372","author":"RE Boeschoten","year":"2017","unstructured":"Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, Uitdehaag BMJ (2017) Prevalence of depression and anxiety in Multiple Sclerosis: a systematic review and meta-analysis. J Neurol Sci 372:331\u2013341. https:\/\/doi.org\/10.1016\/j.jns.2016.11.067","journal-title":"J Neurol Sci"},{"key":"13701_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1212\/wnl.46.3.628","volume":"46","author":"AD Sadovnick","year":"1996","unstructured":"Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K et al (1996) Depression and multiple sclerosis. Neurology 46:628\u2013632. https:\/\/doi.org\/10.1212\/wnl.46.3.628","journal-title":"Neurology"},{"key":"13701_CR5","unstructured":"World Health Organization (2024) Anxiety disorders. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/anxiety-disorders. Accessed 17 Oct 2024"},{"key":"13701_CR6","unstructured":"World Health Organization (2024) Depressive disorder (depression). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression. Accessed 17 Oct 2024"},{"key":"13701_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/jnnp.2004.054635","volume":"76","author":"RJ Siegert","year":"2005","unstructured":"Siegert RJ, Abernethy DA (2005) Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 76:469\u2013475. https:\/\/doi.org\/10.1136\/jnnp.2004.054635","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13701_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/13524585241249564","volume":"30","author":"LM Hancock","year":"2024","unstructured":"Hancock LM (2024) Depression is a core symptom of multiple sclerosis: yes. Mult Scler 30:785\u2013786. https:\/\/doi.org\/10.1177\/13524585241249564","journal-title":"Mult Scler"},{"key":"13701_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1177\/13524585241245653","volume":"30","author":"VM Leavitt","year":"2024","unstructured":"Leavitt VM (2024) Depression is a core symptom of multiple sclerosis: No. Mult Scler 30:787\u2013788. https:\/\/doi.org\/10.1177\/13524585241245653","journal-title":"Mult Scler"},{"key":"13701_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102261","volume":"44","author":"M Hanna","year":"2020","unstructured":"Hanna M, Strober LB (2020) Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Dis 44:102261. https:\/\/doi.org\/10.1016\/j.msard.2020.102261","journal-title":"Mult Scler Relat Dis"},{"key":"13701_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopsych.2010.04.025","volume":"68","author":"SM Gold","year":"2010","unstructured":"Gold SM, Kern KC, O\u2019Connor MF, Montag MJ, Kim A, Yoo YS et al (2010) Smaller cornu ammonis 2\u20133\/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry 68:553\u2013559. https:\/\/doi.org\/10.1016\/j.biopsych.2010.04.025","journal-title":"Biol Psychiatry"},{"key":"13701_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbi.2021.11.022","volume":"100","author":"J Brasanac","year":"2022","unstructured":"Brasanac J, Ramien C, Gamradt S, Taenzer A, Glau L, Ritter K et al (2022) Immune signature of multiple sclerosis-associated depression. Brain Behav Immun 100:174\u2013182. https:\/\/doi.org\/10.1016\/j.bbi.2021.11.022","journal-title":"Brain Behav Immun"},{"key":"13701_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ana.70020","volume":"98","author":"A Manouchehrinia","year":"2025","unstructured":"Manouchehrinia A, Fitzgerald KC, Salter A, Marrie RA, Alfredsson L, Bernstein CN et al (2025) Depression polygenicity and disease activity and disability worsening in multiple sclerosis. Ann Neurol 98:1057\u20131069. https:\/\/doi.org\/10.1002\/ana.70020","journal-title":"Ann Neurol"},{"key":"13701_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106005","volume":"177","author":"C Wang","year":"2023","unstructured":"Wang C, Zhou Y, Feinstein A (2023) Neuro-immune crosstalk in depressive symptoms of multiple sclerosis. Neurobiol Dis 177:106005. https:\/\/doi.org\/10.1016\/j.nbd.2023.106005","journal-title":"Neurobiol Dis"},{"key":"13701_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251359002","volume":"18","author":"J Smolders","year":"2025","unstructured":"Smolders J, Smets I, Wokke B (2025) Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis. Ther Adv Neurol Disord 18:17562864251359002. https:\/\/doi.org\/10.1177\/17562864251359002","journal-title":"Ther Adv Neurol Disord"},{"key":"13701_CR16","doi-asserted-by":"publisher","first-page":"e2216","DOI":"10.1212\/WNL.0000000000008617","volume":"93","author":"S Binzer","year":"2019","unstructured":"Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A (2019) Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study. Neurology 93:e2216\u2013e2223. https:\/\/doi.org\/10.1212\/WNL.0000000000008617","journal-title":"Neurology"},{"key":"13701_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34545-6","volume":"13","author":"BM Jacobs","year":"2023","unstructured":"Jacobs BM, Daruwalla C, McKeon MO, Al-Najjar R, Simcock-Davies A, Tuite-Dalton K et al (2023) Early depressive symptoms and disability accrual in multiple sclerosis: a UK MS register study. Sci Rep 13:8227. https:\/\/doi.org\/10.1038\/s41598-023-34545-6","journal-title":"Sci Rep"},{"key":"13701_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/1352458508088937","volume":"14","author":"M Koch","year":"2008","unstructured":"Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J (2008) Fatigue, depression and progression in multiple sclerosis. Mult Scler 14:815\u2013822. https:\/\/doi.org\/10.1177\/1352458508088937","journal-title":"Mult Scler"},{"key":"13701_CR19","doi-asserted-by":"publisher","first-page":"e1316","DOI":"10.1212\/WNL.0000000000005302","volume":"90","author":"KA McKay","year":"2018","unstructured":"McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L et al (2018) Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology 90:e1316\u2013e1323. https:\/\/doi.org\/10.1212\/WNL.0000000000005302","journal-title":"Neurology"},{"key":"13701_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae021","volume":"6","author":"F van Puijfelik","year":"2024","unstructured":"van Puijfelik F, Blok KM, Klein Kranenbarg RAM, Rip J, de Beukelaar J, Wierenga-Wolf AF et al (2024) Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis. Brain Commun 6:fcae021. https:\/\/doi.org\/10.1093\/braincomms\/fcae021","journal-title":"Brain Commun"},{"key":"13701_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Frenay C, Oh J, Arrambide G, Moccia M, Pia Amato M et al (2025) Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 24:850\u2013865. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4","journal-title":"Lancet Neurol"},{"key":"13701_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x","journal-title":"Acta Psychiatr Scand"},{"key":"13701_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"key":"13701_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/09638288.2016.1213898","volume":"39","author":"LM van Leeuwen","year":"2017","unstructured":"van Leeuwen LM, Mokkink LB, Kamm CP, de Groot V, van den Berg P, Ostelo R, Uitdehaag BMJ (2017) Measurement properties of the arm function in multiple sclerosis questionnaire (AMSQ): a study based on classical test theory. Disabil Rehabil 39:2097\u20132104. https:\/\/doi.org\/10.1080\/09638288.2016.1213898","journal-title":"Disabil Rehabil"},{"key":"13701_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/135245859800400604","volume":"4","author":"DE Goodkin","year":"1998","unstructured":"Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM et al (1998) Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. Mult Scler 4:480\u2013486. https:\/\/doi.org\/10.1177\/135245859800400604","journal-title":"Mult Scler"},{"key":"13701_CR26","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1212\/wnl.58.8.1294","volume":"58","author":"SR Schwid","year":"2002","unstructured":"Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD (2002) Quantitative functional measures in MS: what is a reliable change? Neurology 58:1294\u20131296. https:\/\/doi.org\/10.1212\/wnl.58.8.1294","journal-title":"Neurology"},{"key":"13701_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/13524585211049397","volume":"28","author":"Z Weinstock","year":"2022","unstructured":"Weinstock Z, Morrow S, Conway D, Fuchs T, Wojcik C, Unverdi M et al (2022) Interpreting change on the symbol digit modalities test in people with relapsing multiple sclerosis using the reliable change methodology. Mult Scler 28:1101\u20131111. https:\/\/doi.org\/10.1177\/13524585211049397","journal-title":"Mult Scler"},{"key":"13701_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102512","volume":"19","author":"H Inojosa","year":"2020","unstructured":"Inojosa H, Schriefer D, Ziemssen T (2020) Clinical outcome measures in multiple sclerosis: a review. Autoimmun Rev 19:102512. https:\/\/doi.org\/10.1016\/j.autrev.2020.102512","journal-title":"Autoimmun Rev"},{"key":"13701_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01046-2","volume":"20","author":"B Zeydan","year":"2020","unstructured":"Zeydan B, Kantarci OH (2020) Impact of age on multiple sclerosis disease activity and progression. Curr Neurol Neurosci Rep 20:24. https:\/\/doi.org\/10.1007\/s11910-020-01046-2","journal-title":"Curr Neurol Neurosci Rep"},{"key":"13701_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/jnnp-2014-307948","volume":"86","author":"MW Koch","year":"2015","unstructured":"Koch MW, Greenfield J, Javizian O, Deighton S, Wall W, Metz LM (2015) The natural history of early versus late disability accumulation in primary progressive MS. J Neurol Neurosurg Psychiatry 86:615\u2013621. https:\/\/doi.org\/10.1136\/jnnp-2014-307948","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13701_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1277477","volume":"14","author":"KM Blok","year":"2023","unstructured":"Blok KM, van Rosmalen J, Tebayna N, Smolders J, Wokke B, de Beukelaar J (2023) Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis. Front Neurol 14:1277477. https:\/\/doi.org\/10.3389\/fneur.2023.1277477","journal-title":"Front Neurol"},{"key":"13701_CR32","doi-asserted-by":"publisher","first-page":"e1921","DOI":"10.1212\/WNL.0000000000008519","volume":"93","author":"MD Goldman","year":"2019","unstructured":"Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS et al (2019) Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology 93:e1921\u2013e1931. https:\/\/doi.org\/10.1212\/WNL.0000000000008519","journal-title":"Neurology"},{"key":"13701_CR33","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D et al (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287\u20133298. https:\/\/doi.org\/10.1093\/brain\/awv258","journal-title":"Brain"},{"key":"13701_CR34","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J et al (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147\u20133161. https:\/\/doi.org\/10.1093\/brain\/awac016","journal-title":"Brain"},{"key":"13701_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/13524585241266180","volume":"30","author":"L Prosperini","year":"2024","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Gasperini C (2024) Disability patterns in multiple sclerosis: a meta-analysis on RAW and PIRA in the real-world context. Mult Scler 30:1309\u20131321. https:\/\/doi.org\/10.1177\/13524585241266180","journal-title":"Mult Scler"},{"key":"13701_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213558","volume":"104","author":"L Kappos","year":"2025","unstructured":"Kappos L, Yiu S, Dahlke F, Coetzee T, Cutter GR, Yuen S et al (2025) Composite confirmed disability worsening\/progression is a useful clinical endpoint for multiple sclerosis clinical trials. Neurology 104:e213558. https:\/\/doi.org\/10.1212\/WNL.0000000000213558","journal-title":"Neurology"},{"key":"13701_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103725","volume":"61","author":"PCG Molenaar","year":"2022","unstructured":"Molenaar PCG, Strijbis EMM, van Munster CEP, Uitdehaag BMJ, Kalkers NF (2022) Cross-sectional and longitudinal correlations between the arm function in multiple sclerosis questionnaire (AMSQ) and other outcome measures in multiple sclerosis. Mult Scler Relat Disord 61:103725. https:\/\/doi.org\/10.1016\/j.msard.2022.103725","journal-title":"Mult Scler Relat Disord"},{"key":"13701_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251349354","author":"S Cruz Rivera","year":"2025","unstructured":"Cruz Rivera S, Buxhoeveden S, Aiyegbusi OL, Bozinov N, Kamudoni P, McBurney R, Calvert M (2025) The importance of patient-reported outcomes: a call for their integration in the routine care of patients with multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/13524585251349354","journal-title":"Mult Scler"},{"key":"13701_CR39","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/0269215507074056","volume":"21","author":"L Vahter","year":"2007","unstructured":"Vahter L, Kreegipuu M, Talvik T, Gross-Paju K (2007) One question as a screening instrument for depression in people with multiple sclerosis. Clin Rehabil 21:460\u2013464. https:\/\/doi.org\/10.1177\/0269215507074056","journal-title":"Clin Rehabil"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13701-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13701-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13701-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:09:59Z","timestamp":1774516199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13701-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["13701"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13701-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joost S received research support from Biogen, Roche, Siemens Healthineers and Hansa Biopharma, and lecture and\/or consultancy fee from Biogen, Merck, Novartis, Roche, and Sanofi. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The SPIN-P study received approval from the medical ethics committee of the Erasmus Medical Centre in Rotterdam (MEC-2019-0845). All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"182"}}